Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial

BACKGROUND: To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC). METHODS: In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Anne Katrin, Lücke, Stephan, Abel, Ulrich, Haag, Georg Martin, Grüllich, Carsten, Stange, Annika, Dietrich, Mareike, Apostolidis, Leonidas, Freitag, Angelika, Trierweiler, Claudia, von Gall, Carl, Ose, Jennifer, Giesel, Frederik, Weber, Tim Frederik, Lordick, Florian, Haberkorn, Uwe, Jäger, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048023/
https://www.ncbi.nlm.nih.gov/pubmed/29961759
http://dx.doi.org/10.1038/s41416-018-0152-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048023/
https://www.ncbi.nlm.nih.gov/pubmed/29961759
http://dx.doi.org/10.1038/s41416-018-0152-4

Ejemplares similares